Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Paclitaxel in Advanced Gastric Cancer
NCT03286244Phase 1Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorolanib in gastric cancer (GC), sponsored by AnewPharma Company, Ltd. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Status: unknown.
02
Drugs
vorolanib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03286244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286244.